PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
49.84
+0.29 (0.59%)
Jun 27, 2025, 4:00 PM - Market closed
PTC Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 1,773 | 806.78 | 937.82 | 698.8 | 538.59 | 380.77 | Upgrade
| |
Revenue Growth (YoY) | 91.12% | -13.97% | 34.20% | 29.75% | 41.45% | 24.04% | Upgrade
|
Cost of Revenue | 582.84 | 591.88 | 732.05 | 696.17 | 573.01 | 442.99 | Upgrade
|
Gross Profit | 1,190 | 214.9 | 205.77 | 2.63 | -34.42 | -62.22 | Upgrade
|
Selling, General & Admin | 308.6 | 300.91 | 332.54 | 326 | 285.77 | 244.46 | Upgrade
|
Operating Expenses | 321.61 | 361.65 | 555.18 | 442.55 | 340.52 | 281.36 | Upgrade
|
Operating Income | 868.31 | -146.75 | -349.4 | -439.93 | -374.94 | -343.58 | Upgrade
|
Interest Expense | -169.96 | -170.39 | -128.88 | -90.87 | -86.02 | -56.35 | Upgrade
|
Interest & Investment Income | 6.31 | - | - | - | - | - | Upgrade
|
Currency Exchange Gain (Loss) | -7.6 | - | 9 | -31.3 | - | - | Upgrade
|
Other Non Operating Income (Expenses) | 101.06 | 98.12 | 2.81 | -0.62 | -45.19 | 51.63 | Upgrade
|
EBT Excluding Unusual Items | 798.11 | -219.02 | -466.48 | -562.71 | -506.15 | -348.3 | Upgrade
|
Merger & Restructuring Charges | - | - | - | - | - | -0.3 | Upgrade
|
Gain (Loss) on Sale of Investments | 8.49 | 11.73 | -1.98 | -17.29 | -12.69 | 33.56 | Upgrade
|
Asset Writedown | -168.08 | -168 | -217.8 | -33.38 | - | -54 | Upgrade
|
Other Unusual Items | 12.88 | 12.18 | -9.86 | 25.9 | 0.5 | -33.89 | Upgrade
|
Pretax Income | 651.41 | -363.12 | -696.11 | -587.49 | -518.34 | -402.93 | Upgrade
|
Income Tax Expense | 56.56 | 0.18 | -69.51 | -28.47 | 5.56 | 35.23 | Upgrade
|
Net Income | 594.84 | -363.3 | -626.6 | -559.02 | -523.9 | -438.16 | Upgrade
|
Net Income to Common | 594.84 | -363.3 | -626.6 | -559.02 | -523.9 | -438.16 | Upgrade
|
Shares Outstanding (Basic) | 77 | 77 | 75 | 72 | 70 | 66 | Upgrade
|
Shares Outstanding (Diluted) | 79 | 77 | 75 | 72 | 70 | 66 | Upgrade
|
Shares Change (YoY) | 5.01% | 2.68% | 4.33% | 1.79% | 6.72% | 12.17% | Upgrade
|
EPS (Basic) | 7.70 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | Upgrade
|
EPS (Diluted) | 7.51 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | Upgrade
|
Free Cash Flow | 693.02 | -114.19 | -186.86 | -388.67 | -279.55 | -211.91 | Upgrade
|
Free Cash Flow Per Share | 8.74 | -1.49 | -2.50 | -5.42 | -3.97 | -3.21 | Upgrade
|
Gross Margin | 67.12% | 26.64% | 21.94% | 0.38% | -6.39% | -16.34% | Upgrade
|
Operating Margin | 48.98% | -18.19% | -37.26% | -62.95% | -69.62% | -90.23% | Upgrade
|
Profit Margin | 33.55% | -45.03% | -66.81% | -80.00% | -97.27% | -115.07% | Upgrade
|
Free Cash Flow Margin | 39.09% | -14.15% | -19.92% | -55.62% | -51.90% | -55.66% | Upgrade
|
EBITDA | 895.8 | -71.08 | -112.81 | -311.09 | -310.81 | -300.09 | Upgrade
|
EBITDA Margin | 50.53% | -8.81% | -12.03% | -44.52% | -57.71% | -78.81% | Upgrade
|
D&A For EBITDA | 27.49 | 75.66 | 236.59 | 128.84 | 64.13 | 43.49 | Upgrade
|
EBIT | 868.31 | -146.75 | -349.4 | -439.93 | -374.94 | -343.58 | Upgrade
|
EBIT Margin | 48.98% | -18.19% | -37.26% | -62.95% | -69.62% | -90.23% | Upgrade
|
Revenue as Reported | 1,773 | 806.78 | 937.82 | 698.8 | 538.59 | 380.77 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.